UCB Korea said its dual inhibitor targeting interleukin-17A and 17F, Bimzelx (ingredient: bimekizumab), has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of moderate-to-severe plaque psoriasis in adults who require phototherapy or systemic therapy. According to UCB, Bimzelx is the first and only treatment for plaque psoriasis that simultaneously inhibits IL-17A and IL-17F, cytokines that play a central role in the inflammatory process associated with psoriasis. ....
Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chr...
Bimzelx is an injectable medicine. Here’s how it treats moderate to severe plaque psoriasis.
Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases. It typically presents as red patches with white scales on top. Areas of the body most commonly affected are...
Plaque psoriasis is an autoimmune condition that can affect your skin, including your scalp. Prescription and over-the-counter medications can reduce symptoms.
Skyrizi is an injectable monoclonal antibody. Here’s how it treats plaque psoriasis.
Compare risks and benefits of common medications used for Plaque Psoriasis. Find the most popular drugs, view ratings and user reviews.
We spoke with Dr. Jennifer Soung to uncover the causes of plaque psoriasis, dispel common myths, and discuss treatment options that really work.
Psoriasis, which manifests most often as plaque psoriasis, is a chronic, relapsing, inflammatory skin disorder with a strong genetic basis. Plaque psoriasis (see the image below) is rarely life thr...
Taltz is a monoclonal antibody. Here’s how it treats plaque psoriasis.